IBI is a recent spin out from Interface Biologics, Inc. following the sale of its Surface Modification business. IBI is focused on a novel, non-polymeric, small molecule prodrug platform which provides sustained zero-order release kinetics across a broad range of drug classes and form factors. Our initial product focus is an intravitreal dexamethasone prodrug implant targeting diabetic macular edema, retinal vein occlusion and non-infectious uveitis - collectively a $1B+ market opportunity. The target product profile is to have zero-order drug release for 9-12 months with 1/10th the drug loading of the market leading commercial product with a 30g needle. With strong pre-clinical data and a 505(b)(2) pathway confirmed with the FDA, we are targeting a Phase II clinical trial in mid 2020. Our pipeline product focus areas include other ophthalmic prodrug applications as well as pain management therapies using our steroidal prodrug platform.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
IBE-814 dexamethasone prodrug intravitreal injection
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):